pharma · Advanced Systemic Mastocytosis · Systemic Mastocytosis
Blueprint Medicines (Netherlands) B.V.
Blueprint Medicines drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Blueprint Medicines drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Platelet-derived growth factor receptor alpha.
US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
Development asset linked to Blueprint Medicines in public FDA and regional records.
US regulatory status: approved. Molecular target: Copper.
Development asset linked to Blueprint Medicines in public FDA and regional records.
Development asset linked to Blueprint Medicines in public FDA and regional records.
Development asset linked to Blueprint Medicines in public FDA and regional records.
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.